Solid tumor

China’s new drug Aumolertinib Mesilate Tablets: The world’s second EGFR-targeted therapy for lung cancer with gene mutations.

China’s new drug Aumolertinib Mesilate Tablets: The world’s second EGFR-targeted therapy for lung cancer with gene mutations. #LungCancer #EGFRInhibitor #TargetedTherapy #Aumolertinib #NSCLC Aumolertinib Mesilate Tablets (Ameile) were approved for marketing in China on March 18, 2020. It is China’s first third-generation EGFR-targeted therapy for lung cancer with gene mutations and the second such drug globally, Read More

September 4th,2024 Solid tumor

Breaking Ground: The First Nectin-4 Targeted ADC Approved in China – Urothelial Carcinoma

**Breaking Ground: The First Nectin-4 Targeted ADC Approved in China** #UrothelialCarcinoma #Nectin4 #ADC On August 19, the National Medical Products Administration (NMPA) of China officially approved the innovative antibody-drug conjugate (ADC), Enfortumab Vedotin, developed by Astellas and Pfizer. This groundbreaking approval marks the first Nectin-4 targeted ADC to receive approval in China, providing a new Read More

August 20th,2024 Solid tumor

**Chinese Biopharmaceuticals: Ushering in a New Era in Nasopharyngeal Carcinoma Treatment, EBV-Specific CAR-T Injection Approved for Phase II Clinical Trials in the US and China**

**Chinese Biopharmaceuticals: Ushering in a New Era in Nasopharyngeal Carcinoma Treatment, EBV-Specific CAR-T Injection Approved for Phase II Clinical Trials in the US and China** #Nasopharyngeal #Carcinoma #BRG01 #CART #EBVspecific Biosyngen has announced a milestone achievement: the company’s independently developed BRG01 injection (EBV-specific CAR-T) has received formal written approval from the U.S. Food and Drug Read More

August 14th,2024 Solid tumor , CAR-T

**A Groundbreaking ADC Drug for Cervical Cancer Approved in China Macau**

**A Groundbreaking ADC Drug for Cervical Cancer Approved in China Macau** On August 6, 2024, Zai Lab proudly announced the approval of TIVDAK® (tisotumab vedotin-tftv) in Macau, marking the world’s first ADC (antibody-drug conjugate) specifically for cervical cancer. This innovative treatment is intended for patients with recurrent or metastatic cervical cancer who have experienced disease Read More

August 13th,2024 Solid tumor

Hope to Eradicate Lung Cancer, Colorectal Cancer, and Various Solid Tumors! China’s First Self-Replicating mRNA Vaccine JCXH-211 Successfully Launched~

Hope to Eradicate Lung Cancer, Colorectal Cancer, and Various Solid Tumors! China’s First Self-Replicating mRNA Vaccine JCXH-211 Successfully Launched~ Tumor immunotherapy, as an emerging method for diagnosing and treating tumors, has garnered widespread attention since its inception. Prior to the advent of tumor immunotherapy, the clinical treatment of solid tumors relied solely on traditional surgical Read More

July 10th,2024 Solid tumor

Successful CAR-T Treatment for Advanced Gastric Cancer! Beneficial for Liver Cancer, Brain Tumors, Pancreatic Cancer, with a DCR of 96.1%

According to a report by People’s Daily on April 6, 2023, China has achieved another milestone in the CAR-T field. Recently, China Jiangxi Province successfully completed its first case of CAR-T cell therapy for solid tumors. This not only represents a significant breakthrough in new cancer treatment technologies in Jiangxi but also marks a major advancement in China’s CAR-T research and application.

July 9th,2024 Solid tumor , CAR-T